10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer , breast cancer , multiple myeloma, leukemia and lung cancer . KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1
In Vitro
KRAS inhibitor-10 (0.1-50 µΜ; 72 hours) has antiproliferative effects in KRas mutant tumor cells, KRAS inhibitor-10 is against A549 (lung carcinoma cell line bearing KRas G12S oncogenic mutation), H358 (non-small cell lung cancer line bearing KRas G12C oncogenic mutation), PANC-1 (epithelioid carcinoma of the pancreas cell line bearing KRas G12D oncogenic mutation) and RPMI (myeloma cell line bearing KRas G12A oncogenic mutation) cell proliferation with IC 50 values of 0.2 μM, 0.2 μM, 0.1 μM and 0.8 μM, respectively. KRAS inhibitor-10 (0-1 μM, 7 days) is against cell viability in a 3D CellTiter-GloTM cell viability assay for NIH-H358 cell, the IC 50 value is 0.413 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
KRAS inhibitor-10 (oral administration; 20 mg/kg; BID; 27 days) is safe and tolerate for the bearing mice. KRAS inhibitor-10 demonstrates significant oral anti-tumor activities in vivo. And the tumor growth inhibition (TGI) value is 48.22% for KRAS inhibitor-10 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Subcutaneous NCI-H358 Human Lung Cancer Model in NCr nude mice Dosage: 20 mg/kg Administration: Oral administration; 20 mg/kg; BID; 27 days Result: Decreased tumor volume and exhibited anti-tumor effects in the bearing mice.
IC50& Target:KRas G12C
| Molecular Weight | 519.63 |
|---|
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →
